CN102355896A - 治疗糖尿病的组合物和方法 - Google Patents

治疗糖尿病的组合物和方法 Download PDF

Info

Publication number
CN102355896A
CN102355896A CN201080004432XA CN201080004432A CN102355896A CN 102355896 A CN102355896 A CN 102355896A CN 201080004432X A CN201080004432X A CN 201080004432XA CN 201080004432 A CN201080004432 A CN 201080004432A CN 102355896 A CN102355896 A CN 102355896A
Authority
CN
China
Prior art keywords
compositions
substrate
delivery system
acid
mutually
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201080004432XA
Other languages
English (en)
Chinese (zh)
Inventor
J·R·塞夫奇克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biokier Inc
Original Assignee
Biokier Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biokier Inc filed Critical Biokier Inc
Priority to CN201810694080.3A priority Critical patent/CN109730986A/zh
Publication of CN102355896A publication Critical patent/CN102355896A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Reproductive Health (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
CN201080004432XA 2009-01-12 2010-01-11 治疗糖尿病的组合物和方法 Pending CN102355896A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201810694080.3A CN109730986A (zh) 2009-01-12 2010-01-11 治疗糖尿病的组合物和方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US14395109P 2009-01-12 2009-01-12
US61/143951 2009-01-12
US29377310P 2010-01-11 2010-01-11
US61/293773 2010-01-11
PCT/US2010/020629 WO2010081079A2 (en) 2009-01-12 2010-01-11 Composition and method for treatment of diabetes

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201810694080.3A Division CN109730986A (zh) 2009-01-12 2010-01-11 治疗糖尿病的组合物和方法

Publications (1)

Publication Number Publication Date
CN102355896A true CN102355896A (zh) 2012-02-15

Family

ID=42317190

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201080004432XA Pending CN102355896A (zh) 2009-01-12 2010-01-11 治疗糖尿病的组合物和方法

Country Status (23)

Country Link
US (2) US8470885B2 (enExample)
EP (1) EP2376077B1 (enExample)
JP (1) JP5702306B2 (enExample)
KR (4) KR20170138573A (enExample)
CN (1) CN102355896A (enExample)
AU (1) AU2010203413B2 (enExample)
BR (1) BRPI1006145B8 (enExample)
CA (1) CA2748827C (enExample)
CL (1) CL2011001692A1 (enExample)
CY (1) CY1119010T1 (enExample)
DK (1) DK2376077T3 (enExample)
EA (1) EA022631B1 (enExample)
ES (1) ES2628233T3 (enExample)
HR (1) HRP20170886T1 (enExample)
HU (1) HUE034551T2 (enExample)
LT (1) LT2376077T (enExample)
MX (1) MX2011007393A (enExample)
PL (1) PL2376077T3 (enExample)
PT (1) PT2376077T (enExample)
RS (1) RS56054B1 (enExample)
SI (1) SI2376077T1 (enExample)
SM (1) SMT201700278T1 (enExample)
WO (1) WO2010081079A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107684550A (zh) * 2016-08-03 2018-02-13 徐天宏 糖尿病治疗产品及其制备与应用

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2364161B1 (en) * 2008-11-26 2020-03-11 Satiogen Pharmaceuticals, Inc. Compositions containing satiogens and methods of use
US20150224081A1 (en) * 2009-01-12 2015-08-13 Biokier, Inc. Composition and method for treatment of diabetes
WO2012151252A2 (en) * 2011-05-02 2012-11-08 Biokier, Inc. Composition and method for treatment of diabetes
US20220071895A1 (en) * 2009-01-12 2022-03-10 Biokier, Inc. Composition and method for treatment of diabetes
US9144586B2 (en) 2010-04-07 2015-09-29 Incube Labs, Llc Method for treating glucose related disorders using stem cell-derived gastro-intestinal cells
WO2011143511A2 (en) 2010-05-12 2011-11-17 Columbia University Methods for producing enteroendocrine cells that make and secrete insulin
KR20130055220A (ko) 2011-11-18 2013-05-28 삼성전자주식회사 동박적층판 및 이를 사용한 금속코어기판의 제조방법
JP6089042B2 (ja) * 2011-11-21 2017-03-01 エマウス メディカル インコーポレイテッド 糖尿病及び関連症状の治療のための方法及び組成物
US20150073057A1 (en) * 2013-09-06 2015-03-12 Biokier, Inc. Composition and method for treatment of diabetes
EP3160503B1 (en) 2014-06-26 2021-02-17 The Trustees of Columbia University in the City of New York Inhibition of serotonin expression in gut enteroendocrine cells results in conversion to insulin-positive cells
CN114366802A (zh) * 2015-04-22 2022-04-19 西达-赛奈医疗中心 用于治疗2型糖尿病的肠内递送的苦味寡肽
WO2016210384A2 (en) 2015-06-25 2016-12-29 Synlogic, Inc. Bacteria engineered to treat metabolic diseases
US9668991B1 (en) 2015-12-09 2017-06-06 International Business Machines Corporation SCFA colonic composition
JOP20190146A1 (ar) 2016-12-19 2019-06-18 Axcella Health Inc تركيبات حمض أميني وطرق لمعالجة أمراض الكبد
US20210084956A1 (en) 2018-02-23 2021-03-25 Ambra Bioscience Llc Compositions and methods for hunger control and weight management
CN112839643A (zh) 2018-06-20 2021-05-25 胺细拉健康公司 用于治疗肌肉中脂肪浸润的组合物及方法
CN114340615A (zh) 2019-08-12 2022-04-12 麻省理工学院 用于施用治疗剂的制品和方法
US20230190686A1 (en) * 2021-12-17 2023-06-22 Biokier, Inc. Composition and method for treatment of diabetes

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0302481A2 (en) * 1987-08-07 1989-02-08 Century Laboratories Inc. Use of free fatty acids for the manufacture of a medicament for treatment of diabetes mellitus
EP0509335A1 (en) * 1991-04-12 1992-10-21 ALFA WASSERMANN S.p.A. Gastroresistant pharmaceutical formulations for oral administration containing bile acids
EP1790333A1 (en) * 2005-10-21 2007-05-30 Promefarm s.r.l. Gastroresistant tablet comprising a butyric acid compound
US7431943B1 (en) * 1999-06-14 2008-10-07 Cosmo Technologies Limited Controlled release and taste masking oral pharmaceutical compositions

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999007342A1 (en) 1997-08-11 1999-02-18 Alza Corporation Prolonged release active agent dosage form adapted for gastric retention
US6652882B1 (en) 1997-10-06 2003-11-25 Intellipharmaceutics Corp Controlled release formulation containing bupropion
GB9722426D0 (en) 1997-10-23 1997-12-24 Univ London Pharmacy Controlled release formulations
IL142650A (en) 1998-04-08 2007-06-03 Galmed Int Ltd Use of bile acid conjugates or bile salts and fatty acids or fatty acids in the preparation of pharmaceuticals for lowering cholesterol, for the treatment of fatty liver and for the treatment of hyperglycemia and diabetes
DE60230591D1 (de) 2001-02-26 2009-02-12 Kissei Pharmaceutical Glykopyranosyloxypyrazolderivate und deren medizinische verwendung
US20030203004A1 (en) * 2002-04-24 2003-10-30 Kelm Gary Robert Compositions comprising short and long chain fatty acids and methods of their use for the management of body weight
US7135575B2 (en) * 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
EP1506963B1 (en) 2003-10-28 2005-04-13 Adorkem Technology SpA Method for the preparation of citalopram
ITMI20040187A1 (it) 2004-02-06 2004-05-06 Cosmo Spa Composizioni farmaceutiche o dietetiche a base di acidi grassi a catena corta e zuccheri complessi per le disfunzioni intestinali
ITMI20041295A1 (it) 2004-06-25 2004-09-25 Cosmo Spa Composizioni farmaceutiche antimicrobiche orali
JP2006056881A (ja) 2004-07-21 2006-03-02 Takeda Chem Ind Ltd 縮合環化合物
JP2006063064A (ja) 2004-07-27 2006-03-09 Takeda Chem Ind Ltd 受容体作動剤
AU2006250354A1 (en) 2005-05-23 2006-11-30 Japan Tobacco Inc. Pyrazole compound and therapeutic agent for diabetes comprising the same
DE102005046237A1 (de) * 2005-09-28 2007-04-05 Südzucker Aktiengesellschaft Mannheim/Ochsenfurt Buttersäureester von Kohlenhydraten und Kohlenhydratpolyolen
KR20080089494A (ko) 2006-01-20 2008-10-06 스미스클라인 비참 코포레이션 화합물
WO2008067219A2 (en) 2006-11-29 2008-06-05 Kalypsys, Inc. Quinazolinone modulators of tgr5
CA2673054C (en) * 2006-12-15 2016-05-10 Tima Foundation Novel compositions and uses thereof
EP2364161B1 (en) * 2008-11-26 2020-03-11 Satiogen Pharmaceuticals, Inc. Compositions containing satiogens and methods of use
WO2010062861A2 (en) 2008-11-26 2010-06-03 Satiogen Pharmaceuticals, Inc. Bile acid recycling inhibitors for treatment of obesity and diabetes
SG173612A1 (en) 2009-02-10 2011-09-29 Amarin Pharma Inc Use of eicosapentaenoic acid ethyl ester for treating hypertriglyceridemia
KR102012111B1 (ko) 2009-06-15 2019-08-19 아마린 파마, 인크. 병용 스타틴 요법을 받는 대상체에서 ｌｄｌ－ｃ 수준을 상승시키지 않으면서 트리글리세리드를 저하시키기 위한 조성물 및 방법
BR122019016628B8 (pt) 2009-09-23 2021-07-27 Amarin Corp Plc uso de uma composição compreendendo um derivado de hidróxi de atorvastatina ou sal farmaceuticamente aceitável do mesmo e um óleo compreendendo etil eicosapentaenoato ou etil docosahexaenoato para a fabricação de um medicamento para o tratamento de uma doença cardiovascular

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0302481A2 (en) * 1987-08-07 1989-02-08 Century Laboratories Inc. Use of free fatty acids for the manufacture of a medicament for treatment of diabetes mellitus
EP0509335A1 (en) * 1991-04-12 1992-10-21 ALFA WASSERMANN S.p.A. Gastroresistant pharmaceutical formulations for oral administration containing bile acids
US7431943B1 (en) * 1999-06-14 2008-10-07 Cosmo Technologies Limited Controlled release and taste masking oral pharmaceutical compositions
EP1790333A1 (en) * 2005-10-21 2007-05-30 Promefarm s.r.l. Gastroresistant tablet comprising a butyric acid compound

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
JERRY R GREENFIELD, ET AL.: "oral glutamine increases circulating glucagon-like peptide 1, glucagon, and insulin concentrations in lean, obese, and type 2 diatetic subjects", 《AM J CLIN NUTR》 *
REIMANN F., ET AL.: "glutamine potently stimulates glucagon-like peptide-1 secretion from GLUTag cells", 《DEABETOLOGIA》 *
SHIN-ICHIRO KARAKI ET AL: "Short-chain fatty acid receptor, GPR43, is expressed by enteroendocrine cells and mucosal mast cells in rat intestine", 《CELL AND TISSUE RESEARCH》 *
付永艳等: "结肠靶向给药系统研究概况", 《天津药学》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107684550A (zh) * 2016-08-03 2018-02-13 徐天宏 糖尿病治疗产品及其制备与应用

Also Published As

Publication number Publication date
AU2010203413B2 (en) 2015-05-14
BRPI1006145B1 (pt) 2021-03-09
MX2011007393A (es) 2011-10-06
KR20170138573A (ko) 2017-12-15
PT2376077T (pt) 2017-06-23
AU2010203413A1 (en) 2011-07-14
PL2376077T3 (pl) 2017-10-31
HUE034551T2 (en) 2018-02-28
EA201190068A1 (ru) 2012-01-30
US8470885B2 (en) 2013-06-25
EP2376077A4 (en) 2012-08-29
ES2628233T3 (es) 2017-08-02
WO2010081079A3 (en) 2010-11-25
CY1119010T1 (el) 2018-01-10
EP2376077B1 (en) 2017-03-15
JP2012515163A (ja) 2012-07-05
KR20190062609A (ko) 2019-06-05
BRPI1006145A2 (pt) 2017-05-30
RS56054B1 (sr) 2017-09-29
CL2011001692A1 (es) 2012-04-13
BRPI1006145B8 (pt) 2021-05-25
US8680085B2 (en) 2014-03-25
US20130102581A1 (en) 2013-04-25
DK2376077T3 (en) 2017-06-26
SMT201700278T1 (it) 2017-07-18
US20110275716A1 (en) 2011-11-10
KR20170034928A (ko) 2017-03-29
JP5702306B2 (ja) 2015-04-15
KR20110120866A (ko) 2011-11-04
CA2748827A1 (en) 2010-07-15
HRP20170886T1 (hr) 2017-09-08
EA022631B1 (ru) 2016-02-29
SI2376077T1 (sl) 2017-09-29
LT2376077T (lt) 2017-08-10
WO2010081079A2 (en) 2010-07-15
CA2748827C (en) 2017-10-10
EP2376077A2 (en) 2011-10-19

Similar Documents

Publication Publication Date Title
CN102355896A (zh) 治疗糖尿病的组合物和方法
US9301938B2 (en) Composition and method for treatment of diabetes
AU2012250877B2 (en) Composition and method for treatment of diabetes
US9006288B2 (en) Composition and method for treatment of diabetes
EP2845590A1 (en) Composition for treatment of diabetes
US20190262262A1 (en) Composition and method for treatment of diabetes
US20220071895A1 (en) Composition and method for treatment of diabetes
US20230149300A1 (en) Composition and method for treatment of diabetes
CN109730986A (zh) 治疗糖尿病的组合物和方法
US20220054406A1 (en) Composition and method for treatment of diabetes
US20230133176A1 (en) Composition and method for treatment of diabetes
US20150224081A1 (en) Composition and method for treatment of diabetes
US20230190686A1 (en) Composition and method for treatment of diabetes
US20240000733A1 (en) Composition and method for treatment of diabetes
HK1195004A (en) Composition and method for treatment of diabetes

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination